Oct 27 2018 | Posted In: 20/20 Blog
Chicago, IL — At the American Academy of Ophthalmology meeting, Stanford ophthalmologist, Vinit Mahajan M.D., Ph.D., presented a poster detailing results on the relationship between specific patient mutations and clinical outcomes in the first FDA approved gene therapy trial in humans.